Tirzepatide is a dual GIP/GLP-1 receptor agonist that generally produces greater weight loss than semaglutide in head-to-head trials
The substantial weight loss achieved, alongside the improvements in cardiometabolic markers, suggest that this investigational drug could change how we approach managing this chronic condition
WongMCSHuangJWangJChanPSFLokVChenXet al
PlexusDx also offers GLP-Squared Injection, a proprietary dual-compound combining semaglutide and tirzepatide, at $289/mo month-to-month, or from $249/mo on the 6-month plan for patients who want simultaneous pathway activation or who need medication switching without separate prescriptions
Diabetes Ther 12(12):30933105
Additionally, long-term demand is indirectly reinforced by initiatives that support domestic pharmaceutical manufacturing, preventive healthcare programs, and obesity awareness campaigns